To read the full story, subscribe or sign in.

FDA approves IND application for THRbeta agonist ECC-4703 for NASH

Aug. 1, 2022

The FDA has approved Eccogene's IND application to commence a phase I trial of the company's thyroid hormone receptor (THR) agonist ECC-4703 in the U.S.

BioWorld Science Gastrointestinal

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 17, 2025.

Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA

BioWorld

During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...

23andme founder-led group outbids Regeneron for company

BioWorld

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...

Elevidys’ second liver death hits Sarepta, sends DMD ripples

BioWorld

How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...